NUMAB
LIVE

Serial Number

79266778

Owner

Numab Therapeutics AG

Filing Date

Nov 28, 2018

Add to watchlist:

No watchlists yet
View on USPTO

NUMAB Trademark

Serial Number: 79266778 • Registration: 6274672

NUMAB is a trademark filed by Numab Therapeutics AG on November 28, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Numab Therapeutics AG (2 trademarks)

Einsiedlerstrasse 34

Entity Type: 25

Numab Innovation AG

Einsiedlerstrasse 34

Entity Type: 99

Trademark Details

Filing Date

November 28, 2018

Registration Date

February 23, 2021

Published for Opposition

December 8, 2020

Goods & Services

Medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the fields of immuno-oncology, oncology and immunology; provision of medical information; Medical service featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the nature of preparation and administration of medicines in the field of immuno-oncology, oncology and immunology; advice in connection with dietetics and nutrition; advice with respect to health and provision of health information in the fields of immuno-oncology, oncology and immunology; veterinary services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; hygienic and beauty care for humans and animals; provision of information on diagnostic, prophylactic and therapeutic properties of drugs in the fields of immuno-oncology, oncology and immunology

Research and development services in the field of pharmaceutical preparations, biotechnology, antibodies and antibody fragments, proteins, micro-organisms and cells for therapeutic purposes; research services with respect to pharmaceutical preparations, biotechnology, antibody therapy and gene therapy; scientific and technological services of a chemical and molecular biological laboratory; research, product development and quality control services in the field of pharmacy, medical diagnostics and medical therapy; research services in the field of chemistry and biology; industrial analysis and research services in the field of pharmacy, medical diagnosis, and medical therapy; research and development services for antibody products for therapeutic purposes; conducting and preparing chemical, biochemical and biotechnological analysis and research

Pharmaceutical comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases and other pathologies, treatable or improvable through use of antibodies that bind to, activate or block the target antigens; medicines comprising monoclonal antibodies and/or derivatives thereof for human medicine for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; medicines comprising monoclonal antibodies and/or derivatives thereof for veterinary use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical pharmaceutical products comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; diagnostic preparations for medical use comprising monoclonal antibodies and/or derivatives thereof; chemical preparations comprising monoclonal antibodies and/or derivatives thereof for pharmaceutical use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical preparations for veterinary use comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases

Chemicals, biochemicals, biological preparations and enzymes from biotechnological processes for use in industry and science; chemicals, biochemicals, biological preparations and enzymes, antibodies and antibody fragments, from biotechnological processes, for development and manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof; biological products comprising monoclonal antibodies and/or derivatives thereof, namely, antibodies and antibody fragments for use in laboratories, diagnosis and analysis for scientific and research purposes; chemical and biochemical additives, carriers and substances for manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 23, 2026 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Dec 31, 2023 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Aug 27, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 13, 2021 FINO
CHANGE OF OWNER RECEIVED FROM IB
Jun 6, 2021 CHLD
FINAL DISPOSITION NOTICE SENT TO IB
May 26, 2021 FICS
FINAL DISPOSITION PROCESSED
May 26, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 23, 2021 FICR
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Mar 1, 2021 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Feb 28, 2021 CRCV
REGISTERED-PRINCIPAL REGISTER
Feb 23, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 8, 2020 NPUB
PUBLISHED FOR OPPOSITION
Dec 8, 2020 PUBO
NOTIFICATION PROCESSED BY IB
Dec 6, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 18, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 18, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 18, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 30, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 13, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 13, 2020 CRFA
ASSIGNED TO LIE
Oct 13, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 1, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 6, 2020 GNRN
NON-FINAL ACTION E-MAILED
Mar 6, 2020 GNRT
NON-FINAL ACTION WRITTEN
Mar 6, 2020 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2020 TEME
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Feb 14, 2020 CORN
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 13, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 13, 2020 TROA
CORRECTION TRANSACTION RECEIVED FROM IB
Feb 7, 2020 CRCV
CHANGE OF NAME/ADDRESS REC'D FROM IB
Nov 14, 2019 ADCH
REFUSAL PROCESSED BY IB
Oct 19, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 28, 2019 RFCS
REFUSAL PROCESSED BY MPU
Sep 28, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 18, 2019 RFCR
NON-FINAL ACTION WRITTEN
Sep 17, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Sep 17, 2019 MAFR
ASSIGNED TO EXAMINER
Sep 13, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 13, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 5, 2019 REPR